Return Home

about IAS-USA
news and events
cme programs
course registration
Cases on the Web
publications/guidelines
guidelines
Oral Manifestations Resource Card
Dermatologic Manifestations of HIV
Drug Resistance Mutations
Webcast and Podcasts
Frequently Asked Questions
board and staff
core faculty
donations
contact
home


FACULTY


Judith A. Aberg, MD
Associate Professor of Medicine
Principal Investigator, AIDS Clinical Trials Unit
New York University School of Medicine
Director of HIV Services
Bellevue Hospital Center
New York, NY


Research Topics

  • Immune reconstitution
  • Cardiovascular complications of HIV disease


Lecture and Writing Topics
  • Opportunistic diseases prevention and treatment
  • Cardiovascular complications of HIV disease


Current Professional Summary

Dr Aberg is the Director of HIV Services at Bellevue Hospital Center and an Associate Professor of Medicine at New York University (NYU). She serves as the principal investigator for the NYU AIDS Clinical Trials Unit and on the editorial boards of several clinical journals. She is an attending physician in infectious diseases and virology.


Committees and Organizations

  • Chair, Complications Research Agenda Committee, AIDS Clinical Trials Group
  • Member, Cardiovascular Disease Subcommittee, AIDS Clinical Trials Group
  • Member, Neurology Subcommittee, AIDS Clinical Trials Group
  • Member, Renal Subcommittee, AIDS Clinical Trials Group
  • Member, Scientific Agenda Steering Committee, AIDS Clinical Trials Group
  • Member, Practice Guidelines Committee, Infectious Diseases Society of America (IDSA)
  • Board Member, HIV Medicine Association of the IDSA

Honors and Awards
  • John Carey Young Investigator Award, AIDS Clinical Trials Group (2000)
  • AIDS Foundation of St. Louis: Red Ribbon Award (2004)


Education
  • Pennsylvania State University, College of Medicine, MD (1990)
  • Cleveland Clinic Educational Foundation, Internal Medicine Residency (1990-1993); Chief Medical Resident (1993-1994)
  • Washington University School of Medicine, Department of Infectious Diseases, Fellow (1994-1996)


Selected Publications
  1. Juethner SN, Seyfried W, Aberg JA. Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV Clin Trials. 2003;4:145-149.
  2. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ; Adult AIDS Clinical Trials Group Cardiovascular Subcommittee; HIV Medical Association of the Infectious Disease Society of America. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
  3. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Benowitz NL, Bredt BM, Kosel B, Aberg JA, Deeks SG, Mitchell TF, Mulligan K, Bacchetti P, McCune JM, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003;139:258-266.
  4. Aberg JA. Cardiovascular risk among HIV-positive patients on antiretroviral therapy. J Int Assoc Physicians AIDS Care (Chic Ill). 2003;2(Suppl 2):S24-S39.
  5. Aberg JA, Mundy LM, Powderly WG. Pulmonary cryptococcosis in patients without HIV infection. Chest. 1999;115:734-740.
  6. Ristig MB, Tebas P, Gandy I, Qaqish R, Aberg JA. Cure of acute hepatitis C in HIV co-infection? J Clin Gastroenterol. 2004;38:303.
  7. Mussini C, Pezzotti P, Miro JM, Martinez E, de Quiros JC, Cinque P, Borghi V, Bedini A, Domingo P, Cahn P, Bossi P, de Luca A, d'Arminio Monforte A, Nelson M, Nwokolo N, Helou S, Negroni R, Jacchetti G, Antinori S, Lazzarin A, Cossarizza A, Esposito R, Antinori A, Aberg JA; International Working Group on Cryptococcosis. Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. Clin Infect Dis. 2004;38:565-571.
  8. Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, Wheat LJ, Nyangweso PM, Yiannoutsos CT, Schnizlein-Bick CT, Owens S, Aberg JA; AIDS Clinical Trials Group A5038 Study Group. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis. 2004;38:1485-1489.
  9. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, Aberg J, Hasbun R, Hsu HH. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis. 2004;189:2185-2191.
  10. Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, Stone VE, Kaplan JE; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.Clin Infect Dis. 2004;39:609-629.


Return to Top



© Copyright 2008. International AIDS Society-USA. All rights reserved.
Use of this site is subject to the Visitor's Agreement and Privacy and Confidentiality Policy.
Please read them carefully.